Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases

Not yet recruiting

• Conditions: ImmuNe-Mediated Inflammatory Diseases
• Interventions: Other: Questionnaires

• Registration Number: NCT05172284
• Lead Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Brief Summary

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-12
• Study First Submitted: 2021-12-09
• Study First Submitted QC: 2021-12-13
• Study First Posted: 2021-12-29
• Last Update Submitted: 2022-01-10
• Last Update Posted: 2022-01-11
• Study Start: 2022-02
• Primary Completion: 2023-02
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Patients with a diagnosis of IMID.
• Patients of any age, including minors.
• Patients treated with approved medications for the condition in question and/or phototherapy.
• Patients who agree to sign informed consent.

Exclusion Criteria

• Patients without a diagnosis of IMID.
• Patients who do not consent to sign informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Acne vulgaris	Questionnaires	-
Psoriasis	Questionnaires	-
Atopic dermatitis	Questionnaires	-
Chronic urticaria	Questionnaires	-
Psoriatic arthritis	Questionnaires	-
Chronic eczema of the hands	Questionnaires	-
Contact dermatitis	Questionnaires	-
Vitiligo	Questionnaires	-
Suppurative hydrosadenitis	Questionnaires	-
Systemic lupus erythematosus	Questionnaires	-
Rosacea	Questionnaires	-
Seborrheic dermatitis	Questionnaires	-

Primary Outcome Measures

Name	Time	Method
Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)	15 years	Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies.

Secondary Outcome Measures

Name	Time	Method
PASI 75	15 years	Assess attainment of PASI 75 score from the start of treatment to all follow-ups
PASI 50	15 years	Assess attainment of PASI 50 score from the start of treatment to all follow-ups

Trial Locations

Locations (1)

IRCCS Istituto Ortopedico Galeazzi; 🇮🇹 Milan, Italy